Opioid Induced Constipation Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Opioid Induced Constipation Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Opioid Induced Constipation Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
- Lubiprostone
- Methyl Naltrexone Bromide
- Naldemedine
- Alvimopan
- Others
Segment by Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
By Company
- Ironwood Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Pfizer
- Progenics Pharmaceuticals Inc
- Shionogi & Co., Ltd
- Allergan Plc
- Nektar Therapeutics
- Purdue Pharma
- S.L.A. Pharma AG
- Mundipharma International Limited
- Ono Pharmaceutical Co., Ltd
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma Inc
- Bausch Health
- Cosmo Pharmaceuticals SA
- Daewoong Pharmaceutical
- C.B. Fleet Company
- Sucampo Pharmaceuticals
